Pain Research Group, Institute of Psychology, Jagiellonian University, Kraków, 30-060, Poland.
Department of Nutrition & Drug Research, Faculty of Health Sciences, Institute of Public Health, Jagiellonian University Medical College, Krakow, 31-066, Poland.
J Comp Eff Res. 2022 Aug;11(12):889-904. doi: 10.2217/cer-2022-0031. Epub 2022 Jun 27.
To assess the clinical efficacy and safety profile of opicapone (25 and 50 mg once daily) versus placebo. Levodopa-treated adults with Parkinson's disease. A systematic review and meta-analysis were conducted. Opicapone provided a greater reduction in the absolute OFF-time, increased the chances of ≥1-h reduction in the OFF-time and ≥1-h increase in the ON-time compared with placebo. Receiving opicapone more often facilitated levodopa dose reduction versus placebo. There were no differences in the occurrence of adverse events (severe and leading to drug discontinuation), but receiving opicapone increased the frequency of dyskinesia. Opicapone demonstrated superior clinical efficacy to placebo, with a comparable general safety profile.
评估每日一次口服opicapone（25 和 50 毫克）与安慰剂相比的临床疗效和安全性。接受左旋多巴治疗的帕金森病成人。进行了系统评价和荟萃分析。与安慰剂相比，opicapone 可更大程度地减少绝对关期时间，增加关期时间减少≥1 小时和开期时间增加≥1 小时的机会。与安慰剂相比，接受opicapone 治疗更常导致左旋多巴剂量减少。不良反应（严重且导致药物停药）的发生没有差异，但接受opicapone 治疗会增加发生运动障碍的频率。opicapone 显示出优于安慰剂的临床疗效，具有相当的总体安全性特征。
